Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nolato ABFRA:NBF 76 5-Year Yield-on-Cost % is 3.68 as of Jul. 31, 2026, which is 31% above its 10-year median of 2.81. GuruFocus rates FRA:NBF with a GF Score™ of 76/100 and a GF Value™ of €4.66 (Fairly Valued). The stock has 2 warning signs investors should review. Among 319 Medical Devices & Instruments companies, Nolato AB ranks better than 63.95% on this metric.
Nolato AB's yield on cost for the quarter that ended in Jun. 2026 was 3.68.
The historical rank and industry rank for Nolato AB's 5-Year Yield-on-Cost % or its related term are showing as below:
FRA:NBF'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.34 Med: 2.81 Max: 4.63
Current: 3.68
During the past 13 years, Nolato AB's highest Yield on Cost was 4.63. The lowest was 1.34. And the median was 2.81.
FRA:NBF's 5-Year Yield-on-Cost % is ranked better than 63.95% of 319
companies
in the Medical Devices & Instruments industry
Industry Median: 2.45
vs FRA:NBF: 3.68
Nolato AB (FRA:NBF) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Nolato AB 5-Year Yield-on-Cost % Related Terms
FRA:NBF vs ABT, SYK, MDT: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, Nolato AB's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nolato AB 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nolato AB's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Nolato AB's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Nolato AB is calculated as
Nolato AB (FRA:NBF) has a 5-Year Yield-on-Cost % of 3.68 as of Jul. 31, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Nolato AB and its competitors. This is 31% above median its historical median of 2.81. Over the past decade, Nolato AB's 5-Year Yield-on-Cost % has ranged from 1.34 to 4.63. According to the industry distribution chart, Nolato AB ranks #115 out of 319 companies in the Medical Devices & Instruments industry, placing it in the top 36.1%.
Is Nolato AB's 5-Year Yield-on-Cost % too high?
Nolato AB's current 5-Year Yield-on-Cost % of 3.68 is 31% above median its 10-year median of 2.81. Over the past 10 years, this metric has ranged from a low of 1.34 to a high of 4.63. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.45. Nolato AB's value of 3.68 is 50.2% above this industry median. Based on the distribution chart, Nolato AB ranks #115 out of 319 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Nolato AB has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nolato AB's 5-Year Yield-on-Cost % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nolato AB ranks #115 out of 319 companies for 5-Year Yield-on-Cost %. This puts Nolato AB in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.45. Nolato AB's value of 3.68 is 50.2% above this benchmark. Historically, Nolato AB's own 5-Year Yield-on-Cost % has ranged from 1.34 to 4.63 over the past decade. While the company's 10-year median is 2.81 vs. the industry median of 2.45, Nolato AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.45, based on 319 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nolato AB's current 5-Year Yield-on-Cost % of 3.68 is 50.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Nolato AB and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nolato AB's current 5-Year Yield-on-Cost % is 3.68, which is 31% above median its own 10-year median of 2.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nolato AB stock overvalued right now?
Based on GuruFocus' analysis, Nolato AB (FRA:NBF) is currently considered Fairly Valued. The stock's GF Value™ is €4.66, compared to a current price of €4.28 — trading 8.3% below its estimated fair value. The current 5-Year Yield-on-Cost % is 3.68, which is 31% above median its 10-year median of 2.81 and 50.2% above the Medical Devices & Instruments industry median of 2.45. Nolato AB's overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Nolato AB (FRA:NBF), the current 5-Year Yield-on-Cost % is 3.68 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nolato AB (FRA:NBF) Overvalued in 2026?
Based on GuruFocus' analysis, Nolato AB stock appears to be undervalued.
The current stock price of €4.28 is trading 8.3% below its estimated GF Value™ of €4.66.
GuruFocus considers Nolato AB to be Fairly Valued.
Key valuation signals for FRA:NBF:
5-Year Yield-on-Cost %: 3.68 (31% above median its 10-year median of 2.81)
GF Value™: €4.66 vs. price of €4.28 (8.3% below fair value)
Industry Position: 50.2% above the Medical Devices & Instruments median (#115 of 319)
No single metric tells the full story. See the FRA:NBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nolato AB is a Swedish company that develops and manufactures plastic, silicone, and thermoplastic elastomer products. The firm's operations are organized into two segments: Medical Solutions and Engineered Solutions. The company generates the majority of its revenue from the Medical Solutions segment, which is engaged in the development and manufacture of complex product systems and components for medical devices, the pharmaceutical industry, and diagnostics. The Engineered Solutions design, development, industrialization, and manufacture of subsystems and ready-packaged products for a range of industries, including offerings within EMC and thermal solutions. Geographically, the firm generates key revenue from the Rest of Europe and the United States.
76GF Score
Get the complete analysis for FRA:NBF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NBF has been successfully added to your 
